Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.
Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, Klearman M, Musselman D, Agarwal S, Green J, Kavanaugh A; ADACTA Study Investigators. Gabay C, et al. Lancet. 2013 May 4;381(9877):1541-50. doi: 10.1016/S0140-6736(13)60250-0. Epub 2013 Mar 18. Lancet. 2013. PMID: 23515142 Clinical Trial.
Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial.
Álvaro-Gracia JM, Jover JA, García-Vicuña R, Carreño L, Alonso A, Marsal S, Blanco F, Martínez-Taboada VM, Taylor P, Martín-Martín C, DelaRosa O, Tagarro I, Díaz-González F. Álvaro-Gracia JM, et al. Ann Rheum Dis. 2017 Jan;76(1):196-202. doi: 10.1136/annrheumdis-2015-208918. Epub 2016 Jun 7. Ann Rheum Dis. 2017. PMID: 27269294 Clinical Trial.
Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies.
Sanchez-Piedra C, Diaz-Torne C, Manero J, Pego-Reigosa JM, Rúa-Figueroa Í, Gonzalez-Gay MA, Gomez-Reino J, Alvaro-Gracia JM; BIOBADASER study group. Sanchez-Piedra C, et al. Ann Rheum Dis. 2020 Jul;79(7):988-990. doi: 10.1136/annrheumdis-2020-217948. Epub 2020 Jun 5. Ann Rheum Dis. 2020. PMID: 32503857 Free PMC article. No abstract available.
Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases.
Pablos JL, Abasolo L, Alvaro-Gracia JM, Blanco FJ, Blanco R, Castrejón I, Fernandez-Fernandez D, Fernandez-Gutierrez B, Galindo-Izquierdo M, Gonzalez-Gay MA, Manrique-Arija S, Mena Vázquez N, Mera Varela A, Retuerto M, Seijas-Lopez A; RIER investigators group. Pablos JL, et al. Ann Rheum Dis. 2020 Sep;79(9):1170-1173. doi: 10.1136/annrheumdis-2020-217763. Epub 2020 Jun 12. Ann Rheum Dis. 2020. PMID: 32532753 Free PMC article.
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study.
Pablos JL, Galindo M, Carmona L, Lledó A, Retuerto M, Blanco R, Gonzalez-Gay MA, Martinez-Lopez D, Castrejón I, Alvaro-Gracia JM, Fernández Fernández D, Mera-Varela A, Manrique-Arija S, Mena Vázquez N, Fernandez-Nebro A; RIER Investigators Group; RIER investigators group. Pablos JL, et al. Ann Rheum Dis. 2020 Dec;79(12):1544-1549. doi: 10.1136/annrheumdis-2020-218296. Epub 2020 Aug 12. Ann Rheum Dis. 2020. PMID: 32796045 Free article.
Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study.
Álvaro Gracia JM, Sanchez-Piedra C, Manero J, Ruiz-Lucea ME, López-Vives L, Bohorquez C, Martinez-Barrio J, Bonilla G, Vela P, García-Villanueva MJ, Navío-Marco MT, Pavía M, Galindo M, Erausquin C, Gonzalez-Gay MA, Rua-Figueroa I, Pego-Reigosa JM, Castrejon I, Sanchez-Costa JT, González-Dávila E, Diaz-Gonzalez F; COVIDSER study group. Álvaro Gracia JM, et al. RMD Open. 2021 Dec;7(3):e001925. doi: 10.1136/rmdopen-2021-001925. RMD Open. 2021. PMID: 34887346 Free PMC article.
81 results